Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $3.98 billion versus the consensus estimate of $4.02 billion.

• Revenues of $4.0 billion
• GAAP diluted EPS of $0.07
• Non-GAAP diluted EPS of $0.63
• Cash flow used in operating activities of $405 million
• Free cash flow of $59 million

"We have improved our profitability and reduced our net debt to $23.2 billion. We have also seen solid performance from our key growth drivers: the biosimilar Truxima® increased its market share to 26%, AUSTEDO® continued its year-over-year growth, and AJOVY® solidified its market share in the U.S. and continues to expand in Europe. Based on our results and expectations for the remainder of the year, we are reaffirming our guidance."

GUIDANCE:

Teva Pharma sees FY2021 EPS of $2.50-$2.70, versus the consensus of $2.61. Teva Pharma sees FY2021 revenue of $16.4-16.8 billion, versus the consensus of $16.68 billion.

Full year 2021 business outlook reaffirmed:

• Net revenues of $16.4-16.8 billion
• EBITDA of $4.8 - $5.1 billion
• EPS of $2.50 - $2.70
• Free cash flow of $2.0 - $2.3 billion

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.